Cargando…
Real-World Treatment Patterns and Switching Following Moderate/Severe Chronic Obstructive Pulmonary Disease Exacerbation in Patients with Commercial or Medicare Insurance in the United States
PURPOSE: There is limited literature regarding real-world treatment patterns of patients with COPD, particularly since the introduction of once-daily single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol in 2017. Here, we evaluated treatment patterns of patients with COPD be...
Autores principales: | Bogart, Michael, Germain, Guillaume, Laliberté, François, Lejeune, Dominique, Duh, Mei Sheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377554/ https://www.ncbi.nlm.nih.gov/pubmed/37521022 http://dx.doi.org/10.2147/COPD.S398816 |
Ejemplares similares
-
Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population
por: Bogart, Michael, et al.
Publicado: (2019) -
Real‐World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B‐Cell Lymphoma in the U.S
por: Yang, Xiaoqin, et al.
Publicado: (2021) -
Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US
por: Bogart, Michael, et al.
Publicado: (2023) -
Characterizing Real-World Use Of Tiotropium In Asthma In The USA
por: Averell, Carlyne M, et al.
Publicado: (2019) -
Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation
por: Mannino, David, et al.
Publicado: (2022)